GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cambium Bio Ltd (ASX:CMB) » Definitions » 3-Year Revenue Growth Rate

Cambium Bio (ASX:CMB) 3-Year Revenue Growth Rate : 0.00% (As of Jun. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Cambium Bio 3-Year Revenue Growth Rate?

Cambium Bio's Revenue per Share for the six months ended in Jun. 2024 was A$0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Competitive Comparison of Cambium Bio's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Cambium Bio's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cambium Bio's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cambium Bio's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Cambium Bio's 3-Year Revenue Growth Rate falls into.



Cambium Bio 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Cambium Bio  (ASX:CMB) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


Cambium Bio 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Cambium Bio's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Cambium Bio Business Description

Traded in Other Exchanges
N/A
Address
16 Goodhope Street, Paddington, Sydney, NSW, AUS, 2021
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate Elate Ocular is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.

Cambium Bio Headlines

No Headlines